Skip to content.

Companies

Acquired by Apple

Acquired by Apple

Acquired by Capital D

Acquired by Capital D

Acquired by Oracle

Acquired by Oracle

Acquired by Siemens

Acquired by Siemens

Acquired by ERT Inc

Acquired by ERT Inc

IPO: AREC

IPO: AREC

IPO: ORTX

IPO: FRLN

IPO: ACHL

IPO: MGTX

Acquired by Facebook

IPO: BKNG

IPO: GENinCode

IPO: DSS/ Bioclinica

  • Life Sciences investments
  • Investing since
    2016
    In collaboration with UCL Business
  • Total investment
    > $2bn
    Over $2bn of follow on funding for our companies
  • Public offerings
    4 IPOs
    Four Nasdaq IPOs since 2018

Featured investments

What to expect in 2023?

Predictions for 2023

Read the article >
Bloomsbury GTX launches with Seed financing of £5m to develop the promise of gene therapy

Bloomsbury GTX raises £5m Seed funding to develop curative gene therapy treatments

Read the article >

Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet?

Read the article >
Companies
  • Achilles Therapeutics
    Biopharmaceutical company developing precision T cell therapies
    Sector: Life Sciences
    Status: Nasdaq IPO
  • biopharmaceutical company advancing a robust pipeline of potentially transformative therapeutic programs
    Sector: Life Sciences
    Status: Growth
  • Bloomsbury AI
    Enabling everyone to easily create their own question-answering system
    Sector: Life Sciences
    Status: Exited
  • Biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases
    Sector: Life Sciences
    Status: Early Stage
  • Immuno-oncology company targeting cancer with the IgE class of antibodies
    Sector: Life Sciences
    Status: Early Stage
  • Freeline Therapeutics
    Biopharmaceutical company focused on the development of liver-directed gene therapies
    Sector: Life Sciences
    Status: Nasdaq IPO
  • Vertically integrated, clinical stage gene therapy company
    Sector: Life Sciences
    Status: Nasdaq IPO
  • Immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer
    Sector: Life Sciences
    Status: Early Stage
  • Orchard Therapeutics
    Biotechnology company bringing transformative gene therapies to patients with serious and life-threatening orphan diseases
    Sector: Life Sciences
    Status: Nasdaq IPO
  • Panangium Therapeutics
    Biologic for retinal disease targeting a novel alternative pathway to VEGF
    Sector: Life Sciences
    Status: Early Stage
  • Quell Therapeutics
    Cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions
    Sector: Life Sciences
    Status: Growth

Let’s talk